The 2026 edition of our annual report draws on survey insights from 170+ commercial leaders and interviews with experts from Genentech, Pfizer, AstraZeneca, UCB, Denali, and more to explore the operational challenges, trends, and strategies shaping patient experiences today and guiding the way forward, including:

• Where biopharma companies across all segments are prioritizing their investments in 2026
• How legacy infrastructure and data fragmentation are hindering innovation
• How commercial leaders are using AI to scale and automate patient engagement without losing the human connection

Download the report to access the latest trends and see how your program performance compares to industry benchmarks.